Salivary Glutamate is Elevated in Individuals with Chronic Migraine
Overview
Affiliations
Background Glutamate has been implicated in migraine pathogenesis, and is elevated in the plasma, cerebrospinal fluid, and saliva in migraineurs. However, no comparison of glutamate levels among chronic migraine, episodic migraine and controls has been reported. The aim is to compare salivary glutamate levels of individuals with chronic migraine with those of individuals with episodic migraine and healthy controls. Methods We investigated salivary glutamate level of 46 women with chronic migraine, 50 women with episodic migraine, and 19 healthy controls via enzyme linked immunosorbent assay. Results The salivary glutamate level of the chronic migraine group (median and interquartile range, 20.47 [15.27-30.15] pmol/mg total protein) was significantly higher than those of the episodic migraine (16.17 [12.81-20.15] pmol/mg total protein, p = 0.008) and control (12.18 [9.40-16.24] pmol/mg total protein, p = 0.001) groups. The salivary glutamate level of the episodic migraine group was marginally elevated from that of the control group (post hoc p = 0.016). Thresholds of 16.58 and 17.94 pmol/mg total protein optimize the sensitivity and specificity to differentiate chronic migraine participants from healthy controls and episodic migraine participants, respectively. Conclusions Salivary glutamate level was elevated in chronic migraine participants. These data suggest that salivary glutamate level could be an indicator of CM.
Petrusic I, Chiang C, Garcia-Azorin D, Ha W, Ornello R, Pellesi L J Headache Pain. 2025; 26(1):2.
PMID: 39748331 PMC: 11697626. DOI: 10.1186/s10194-024-01944-7.
Proteomics in Patients with Fibromyalgia Syndrome: A Systematic Review of Observational Studies.
Gkouvi A, Tsiogkas S, Bogdanos D, Gika H, Goulis D, Grammatikopoulou M Curr Pain Headache Rep. 2024; 28(7):565-586.
PMID: 38652420 PMC: 11271354. DOI: 10.1007/s11916-024-01244-4.
Human Serum and Salivary Metabolomes: Diversity and Closeness.
Ferrari E, Gallo M, Spisni A, Antonelli R, Meleti M, Pertinhez T Int J Mol Sci. 2023; 24(23).
PMID: 38068926 PMC: 10706786. DOI: 10.3390/ijms242316603.
Migraine Treatment: Towards New Pharmacological Targets.
Silvestro M, Iannone L, Orologio I, Tessitore A, Tedeschi G, Geppetti P Int J Mol Sci. 2023; 24(15).
PMID: 37569648 PMC: 10418850. DOI: 10.3390/ijms241512268.
Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings.
Demartini C, Francavilla M, Zanaboni A, Facchetti S, De Icco R, Martinelli D Int J Mol Sci. 2023; 24(6).
PMID: 36982428 PMC: 10049673. DOI: 10.3390/ijms24065334.